Domperidone in Treating Patients With Gastrointestinal Disorders

Inclusion Criteria: * Patients with GI disorders who have failed standard therapy * Symptoms or manifestations of: a) gastroparesis; b) refractory gastroesophageal reflux disease (GERD) including persistent esophagitis, refractory heartburn, reflux-related laryngitis, and respiratory symptoms; or c) severe dyspepsia * Completion of a comprehensive evaluation, including clinical history and physical examination, to eliminate other causes of their symptoms * Patient has signed the informed consent document agreeing to the use of the study drug, domperidone * White blood cell (WBC) with differential greater than 3,000/ml * Alkaline phosphatase less than 1.5 x upper limit of normal * Alanine aminotransferase (ALT) less than 2 x upper limit of normal * Aspartate aminotransferase (AST) less than 2 x upper limit of normal * Bilirubin less than or equal to 2 x upper limit of normal * Blood urea nitrogen (BUN) less than 2 x upper limit of normal * Creatinine less than 1.5 x upper limit of normal * Stable hemoglobin greater than or equal to 8.0 g/dl * Potassium between range of 3.0 to 5.5 * Magnesium level between 1.6-2.6 mg Exclusion Criteria: * Patients with the following cardiac diagnoses: ventricular tachycardia or fibrillation; Torsade des Pointes; clinically significant bradycardia; sinus node dysfunction; heart block; prolonged QTc interval (QTc \> 450 milliseconds for males, QTc \> 470 milliseconds for females); prior specific cardiovascular conditions of clinically signific…